Clinical Trial Update: A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US

View source ↗

Summary

A completed study comparing Elranatamab (PF-06863135) to standard-of-care therapy in multiple myeloma patients in Germany and the United States has posted resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Elranatamab (elranatamab)
• Standard of Care

Snippet

Sponsor: Pfizer | Conditions: Multiple Myeloma | Status: COMPLETED | Results posted: 2025-06-27